On August 10th, MSQ brought together some of the most influential figures in the field of targeted protein degradation (TPD) in our webinar of “Global Development of Targeted Protein Degradation & Partnership Opportunities – Part 1 .” The event was co-hosted by MSQ Ventures and BioAroundWorld.  

Unveiling What's New, Expert Insights and Viewpoints in Targeted Protein Degradation (TPD) PART 1 

Moderator: Jingzhen (Ginger) Ding Ding, Managing Director, MSQ Ventures 
Speakers: 
Michael Palladinetti, Global Head of BD & Licensing, Sanofi 
Scott Boyle, Ph.D. MBA Boyle, CBO, C4 Therapeutics, Inc. 
Tom S., CEO, Captor Therapeutics SA 
xiaobao yang, CEO, Gluetacs Therapeutics 
Liqiang (Leo) Fu Fu, Co-Founder, GluBio Therapeutics Inc 
Ruo Xu, VP of BD, Kintor Pharmaceutical Limited 

Key Highlights:  

• Sharing by Michael Palladinetti, Global Head of BD & Licensing of Sanofi on the Insights and Impact on Sanofi for Nurix’s $2.56bn TPD Partnership and Kymera’s $2bn Deal  

• Technology highlights of emerging TPD stars - including C4 Therapeutics, Inc., Captor Therapeutics SA, Gluetacs Therapeutics, GluBio Therapeutics Inc and Kintor Pharmaceutical Limited  

• Case studies of recent $35M upfront landmark transaction between C4 Therapeutics, Inc. and Betta Pharmaceuticals Co., Ltd. , and the prediction for emerging deal structures, platform collaboration vs. licensing as partnership strategies, and collaborations beyond oncology  

• The pros and cons of bifunctional degrader vs. molecule glue, and upcoming breakthroughs, for example degrader-antibody conjugates